A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

The primary objective was to demonstrate that basal insulin peglispro (BIL) was non‐inferior compared with insulin glargine (GL) for haemoglobin A1c (HbA1c) at 26 weeks with a non‐inferiority margin of 0.4%.

[1]  Y. Qu,et al.  Glucodynamics of long‐acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial , 2016, Diabetes, obesity & metabolism.

[2]  A. Chang,et al.  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[3]  J. Bue-Valleskey,et al.  Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial , 2016, Diabetes, obesity & metabolism.

[4]  F. Travert,et al.  Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 , 2016, Diabetes, obesity & metabolism.

[5]  A. Chang,et al.  Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials , 2015, Diabetes technology & therapeutics.

[6]  Junxiang Luo,et al.  Estimation of group means when adjusting for covariates in generalized linear models , 2015, Pharmaceutical statistics.

[7]  S. Mudaliar,et al.  Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects , 2014, Diabetes Care.

[8]  K. Mace,et al.  Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects , 2014, Journal of clinical pharmacology.

[9]  T. Heise,et al.  Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[10]  J. M. Beals,et al.  Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism , 2014, Diabetes.

[11]  K. Strauss,et al.  Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. , 2013, Diabetes & metabolism.

[12]  Junxiang Luo,et al.  The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. , 2013, Diabetes technology & therapeutics.

[13]  Junxiang Luo,et al.  Analysis of hypoglycemic events using negative binomial models , 2013, Pharmaceutical statistics.

[14]  J. Rosenstock,et al.  Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes , 2013, Diabetes Care.

[15]  J. McGill,et al.  Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis , 2012, Diabetes/metabolism research and reviews.

[16]  V. Navarro,et al.  Review article: drug‐induced liver injury – its pathophysiology and evolving diagnostic tools , 2011, Alimentary pharmacology & therapeutics.

[17]  Alex Dmitrienko,et al.  General Multistage Gatekeeping Procedures , 2008, Biometrical journal. Biometrische Zeitschrift.

[18]  M. Madariaga,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[19]  R. Landgraf,et al.  Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[20]  H. Hauner,et al.  Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[21]  P. Cryer,et al.  Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. , 1993, The Journal of clinical investigation.

[22]  P. Cryer.  Iatrogenic Hypoglycemia as a Cause of Hypoglycemia-Associated Autonomic Failure in IDDM: A Vicious Cycle , 1992, Diabetes.